SCHEMBL6482575

SCHEMBL6482575

CCN(CC)CCNc1ccc(CCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
RECQL P46063 1/20 0.56
BLM P54132 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
SIRT2 Q8IXJ6 1/20 0.53
PTGS1 P23219 1/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
FABP4 P15090 1/20 0.48
PLK1 P53350 4/20 0.46
MT-CO2 P00403 1/20 0.46
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
TEAD4 Q15561 1/20 0.45
CLCN2 P51788 1/20 0.43
ABCC1 P33527 2/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476651 0.95 MEN1 (0.51) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6474572 0.88 MEN1 (0.48) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475772 0.82 MEN1 (0.76) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482028 0.82 PLK1 (0.57) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6476162 0.81 MEN1 (0.55) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6482855 0.81 SIRT2 (0.77) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6474259 0.81 MEN1 (0.60) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6475044 0.80 CLCN2 (0.46) MEN1KMT2ARECQLBLMTDP1
SCHEMBL13855746 0.80 MEN1 (0.65) MEN1KMT2ARECQLBLMTDP1
SCHEMBL6483326 0.79 MEN1 (0.58) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885RECQL 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.